Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice

Vaccine

Volumn 31, Issue 14, 2013, Pages 1848-1855

  Brewoo, Joseph N ^a   Powell, Tim D ^b   Jones, Jeremy C ^a,d   Gundlach, Nancy A ^a,e   Young, Ginger R ^a   Chu, Haiyan ^a   Das, Subash C ^a   Partidos, Charalambos D ^a   Stinchcomb, Dan T ^b   Osorio, Jorge E ^a,c  

^a Inviragen Inc   (United States)

^b Inviragen Inc   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

Author keywords

Cross protective immunity; Influenza; Modified vaccinia Ankara; Safety; Vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; NUCLEOPROTEIN; RECOMBINANT MODIFIED VACCINIA ANKARA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; DRUG EFFICACY; FLOW CYTOMETRY; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; LETHALITY; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; SINGLE DRUG DOSE; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS REACTIONS; GENETIC VECTORS; HEMAGGLUTININS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINIA VIRUS;

EID: 84875260632     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.038     Document Type: Article

References (41)

1. CDC I. The disease. http://www.cdc.gov/flu/about/disease.htm.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(September (11)):1333-1340.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(January (2)):179-186.
4. Meltzer M.I., Cox N.J., Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5(September-October (5)):659-671.
5. WHO. Global Alert and Response (GAR), Pandemic (H1N1) 2009 - update 112; <>; August 06, 2010 ed, 2010. http://www.who.int/csr/don/2010_08_06/en/index.html.
6. Katz J.M., Lu X., Frace A.M., Morken T., Zaki S.R., Tumpey T.M. Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed Pharmacother 2000, 54(May 4):178-187.
7. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO; <>; May 02, 2012 ed: WHO, 2012. http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.
8. Ghendon Y. The immune response of humans to live and inactivated influenza vaccines. Adv Exp Med Biol 1989, 257:37-45.
9. Mossad S.B. Demystifying FluMist, a new intranasal, live influenza vaccine. Cleve Clin J Med 2003, September (70)(9):801-806.
10. Riddiough M.A., Sisk J.E., Bell J.C. Influenza vaccination. JAMA 1983, 249(June (23)):3189-3195.
11. Jefferson T., Smith S., Demicheli V., Harnden A., Rivetti A. Safety of influenza vaccines in children. Lancet 2005, 366(September (9488)):803-804.
12. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9(August (8)):493-504.
13. Mostow S.R., Schoenbaum S.C., Dowdle W.R., Coleman M.T., Kaye H.S. Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses. Bull World Health Organ 1969, 41(3):525-530.
14. Peck F.B. Purified influenza virus vaccine. A study of viral reactivity and antigenicity. JAMA 1968, 206(December (10)):2277-2282.
15. Hessel A., Schwendinger M., Holzer G.W., Orlinger K.K., Coulibaly S., Savidis-Dacho H., et al. Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One 2011, 6(1):e16247.
16. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52(January (1)):1-7.
17. Kreijtz J.H., Suzer Y., Bodewes R., Schwantes A., van Amerongen G., Verburgh R.J., et al. Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 2010, 91(November (Pt 11)):2745-2752.
18. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001, 19(June (27)):3700-3709.
19. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55(July (1)):19-25.
20. Gilbert P.A., Comanita L., Barrett J., Peters A., Szabat M., McFadden G., et al. Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development. Cytotechnology 2005, 48(June (1-3)):79-88.
21. Hornemann S., Harlin O., Staib C., Kisling S., Erfle V., Kaspers B., et al. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol 2003, 77(August (15)):8394-8407.
22. Reed L.J., Muench H. A simple method of estimating fifty percent points. Am J Hyg 1938, 27:493.
23. Brewoo J.N., Powell T.D., Stinchcomb D.T., Osorio J.E. Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine 2010, August (28)(36):5891-5899.
24. Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW. Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Protein Sci/editorial board, John E Coligan [et al 2001 May; Chapter 5: Unit 5 12.
25. Earl PL, Moss B, Wyatt LS, Carroll MW. Generation of recombinant vaccinia viruses. Curr Protoc Mol Biol/edited by Frederick M Ausubel [et al 2001 May; Chapter 16: Unit 16 7].
26. WHO Manual on animal influenza diagnosis and surveillance 2002, WHO, Geneva, Switzerland.
27. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 2009, 27(October (45)):6296-6299.
28. Kreijtz J.H., Suezer Y., van Amerongen G., de Mutsert G., Schnierle B.S., Wood J.M., et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007, 195(June (11)):1598-1606.
29. Alam S., Sant A.J. Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus. J Virol 2011, 85(December (4)):13310-13321.
30. Chen G.L., Min J.Y., Lamirande E.W., Santos C., Jin H., Kemble G., et al. Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets. Journal Infect Dis 2011, 203(April (7)):930-936.
31. Chen G.L., Lau Y.F., Lamirande E.W., McCall A.W., Subbarao K. Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci U S A 2011, 108(January (3)):1140-1145.
32. Fang Y., Banner D., Kelvin A.A., Huang S.S., Paige C.J., Corfe S.A., et al. Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism. J Virol 2012, 86(February (4)):2229-2238.
33. Sun K., Ye J., Perez D.R., Metzger D.W. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011, 186(January (2)):987-993.
34. Weinfurter J.T., Brunner K., Capuano S.V., Li C., Broman K.W., Kawaoka Y., et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011, 7(November (11)):e1002381.
35. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985, 82(March (6)):1785-1789.
36. McMichael A.J., Michie C.A., Gotch F.M., Smith G.L., Moss B. Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol 1986, 67(April (Pt 4)):719-726.
37. Townsend A.R., Skehel J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 1984, 160(August (2)):552-563.
38. Bui H.H., Peters B., Assarsson E., Mbawuike I., Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A 2007, 104(January (1)):246-251.
39. Ramirez J.C., Gherardi M.M., Rodriguez D., Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000, 74(August (16)):7651-7655.
40. Harrop R., Connolly N., Redchenko I., Valle J., Saunders M., Ryan M.G., et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006, 12(June (11 Pt 1)):3416-3424.
41. Gudmundsdotter L., Nilsson C., Brave A., Hejdeman B., Earl P., Moss B., et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27(July (33)):4468-4474.